• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹膜透析患者的心血管风险。

Cardiovascular risk in the peritoneal dialysis patient.

机构信息

Division of Nephrology, Department of Medicine, Academic Medical Centre University of Amsterdam, P. O. Box 22700, 1100 DE Amsterdam, The Netherlands.

出版信息

Nat Rev Nephrol. 2010 Aug;6(8):451-60. doi: 10.1038/nrneph.2010.68. Epub 2010 Jun 22.

DOI:10.1038/nrneph.2010.68
PMID:20567248
Abstract

Cardiovascular death is the most frequent cause of death in patients on peritoneal dialysis. Risk factors for cardiovascular death in these patients include those that affect the general population as well as those related to end-stage renal disease (ESRD) and those that are specific to peritoneal dialysis. The development of overhydration after loss of residual renal function is probably the most important cardiovascular risk factor specific to peritoneal dialysis. The high glucose load associated with peritoneal dialysis may lead to insulin resistance and to the development of an atherogenic lipid profile. The presence of glucose degradation products in conventional dialysis solutions, which leads to the local formation of advanced glycation end products, is also specific to peritoneal dialysis. Other risk factors that are not specific to peritoneal dialysis but are related to ESRD include calcifications and protein-energy wasting. When present together with inflammation and atherosclerosis, protein-energy wasting is associated with a marked increase in the risk of cardiovascular death. Obesity is not associated with increased cardiovascular risk in patients on any form of dialysis. Left ventricular hypertrophy and increased arterial stiffness are the most important risk factors for cardiovascular events in the general population.

摘要

心血管死亡是腹膜透析患者最常见的死亡原因。这些患者心血管死亡的危险因素包括影响普通人群的因素、与终末期肾病(ESRD)相关的因素以及与腹膜透析相关的特定因素。残余肾功能丧失后发生的水过多可能是腹膜透析特有的最重要的心血管危险因素。与腹膜透析相关的高葡萄糖负荷可能导致胰岛素抵抗和形成动脉粥样硬化脂质谱。在常规透析液中存在葡萄糖降解产物,导致局部形成晚期糖基化终产物,这也是腹膜透析特有的。其他非腹膜透析特有的但与 ESRD 相关的危险因素包括钙化和蛋白质能量消耗。当与炎症和动脉粥样硬化一起存在时,蛋白质能量消耗与心血管死亡风险的显著增加相关。肥胖与任何形式透析患者的心血管风险增加无关。左心室肥厚和动脉僵硬增加是普通人群心血管事件的最重要危险因素。

相似文献

1
Cardiovascular risk in the peritoneal dialysis patient.腹膜透析患者的心血管风险。
Nat Rev Nephrol. 2010 Aug;6(8):451-60. doi: 10.1038/nrneph.2010.68. Epub 2010 Jun 22.
2
Peritoneal dialysis and cardiovascular disease.腹膜透析与心血管疾病
Minerva Urol Nefrol. 2012 Sep;64(3):153-62.
3
The Potential Cardiovascular Benefits of Low-Glucose Degradation Product, Biocompatible Peritoneal Dialysis Fluids: A Review of the Literature.低葡萄糖降解产物生物相容性腹膜透析液对心血管系统的潜在益处:文献综述
Perit Dial Int. 2017 Jul-Aug;37(4):375-383. doi: 10.3747/pdi.2016.00228.
4
Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease.在一个全国性慢性肾病患者队列中比较腹膜透析和血液透析的死亡风险。
Ann Intern Med. 2005 Aug 2;143(3):174-83. doi: 10.7326/0003-4819-143-3-200508020-00003.
5
Strategies for improving long-term survival in peritoneal dialysis patients.提高腹膜透析患者长期生存率的策略。
Clin J Am Soc Nephrol. 2010 Jun;5(6):1123-31. doi: 10.2215/CJN.04300709. Epub 2010 Apr 29.
6
Is peritoneal dialysis associated with increased cardiovascular morbidity and mortality?腹膜透析是否与心血管疾病发病率和死亡率增加相关?
Perit Dial Int. 2006 Jul-Aug;26(4):429-34.
7
Summaries for patients. Effects of dialysis type on survival in patients with end-stage kidney disease.患者摘要。透析类型对终末期肾病患者生存率的影响。
Ann Intern Med. 2005 Aug 2;143(3):I17. doi: 10.7326/0003-4819-143-3-200508020-00001.
8
The clinical and epidemiological aspects of vascular mortality in chronic peritoneal dialysis patients.慢性腹膜透析患者血管性死亡的临床和流行病学特征
Perit Dial Int. 2005 Feb;25 Suppl 3:S80-3.
9
Diabetes mellitus and dialysis.糖尿病与透析
Minerva Urol Nefrol. 2004 Sep;56(3):289-303.
10
Risk of Cardiovascular Disease and Mortality in Young Adults With End-stage Renal Disease: An Analysis of the US Renal Data System.终末期肾病青年患者的心血管疾病风险和死亡率:美国肾脏数据系统分析。
JAMA Cardiol. 2019 Apr 1;4(4):353-362. doi: 10.1001/jamacardio.2019.0375.

引用本文的文献

1
Correlation of the triglyceride-glucose-body mass index with all-cause and cardiovascular mortality in patients undergoing peritoneal dialysis: a retrospective cohort study.甘油三酯-血糖-体重指数与腹膜透析患者全因死亡率和心血管死亡率的相关性:一项回顾性队列研究
Front Nutr. 2025 Aug 20;12:1612402. doi: 10.3389/fnut.2025.1612402. eCollection 2025.
2
Visit-to-visit blood pressure variability as a prognostic marker in peritoneal dialysis: insights from machine learning-based risk models.透析间期血压变异性作为腹膜透析预后标志物:基于机器学习风险模型的见解
Hypertens Res. 2025 Sep;48(9):2471-2472. doi: 10.1038/s41440-025-02283-z. Epub 2025 Jul 4.
3

本文引用的文献

1
B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial.B 族维生素与终末期肾病患者全因死亡率和心血管疾病的关系:一项随机对照试验的结果。
Circulation. 2010 Mar 30;121(12):1432-8. doi: 10.1161/CIRCULATIONAHA.109.904672. Epub 2010 Mar 15.
2
Malnutrition-inflammation score independently determined cardiovascular and infection risk in peritoneal dialysis patients.营养不良-炎症评分可独立确定腹膜透析患者的心血管和感染风险。
Blood Purif. 2010;29(3):308-16. doi: 10.1159/000280641. Epub 2010 Feb 4.
3
Reassessment of albumin as a nutritional marker in kidney disease.
Gut microbiome dynamics of patients on dialysis: implications for complications and treatment.
透析患者的肠道微生物群动态:对并发症和治疗的影响。
Front Pharmacol. 2025 Apr 25;16:1470232. doi: 10.3389/fphar.2025.1470232. eCollection 2025.
4
Dialysis and cognitive impairment.透析与认知障碍。
Nat Rev Nephrol. 2025 Apr 24. doi: 10.1038/s41581-025-00960-3.
5
Explainable machine learning algorithm to predict cardiovascular event in patients undergoing peritoneal dialysis.用于预测腹膜透析患者心血管事件的可解释机器学习算法。
BMC Med Inform Decis Mak. 2025 Apr 22;25(1):172. doi: 10.1186/s12911-025-03003-w.
6
Risk prediction of cardiovascular events in peritoneal dialysis patients.腹膜透析患者心血管事件的风险预测
BMC Nephrol. 2025 Apr 5;26(1):177. doi: 10.1186/s12882-025-04091-6.
7
Inflammatory Burden Index: A Superior Prognostic Biomarker of Systemic Inflammation in Patients on Peritoneal Dialysis.炎症负担指数:腹膜透析患者全身炎症的一种优越的预后生物标志物。
J Inflamm Res. 2024 Dec 11;17:10913-10927. doi: 10.2147/JIR.S393291. eCollection 2024.
8
Estimating Dietary Protein and Sodium Intake with Sodium Removal in Peritoneal Dialysis Patients.评估腹膜透析患者钠清除情况下的膳食蛋白质和钠摄入量
Metabolites. 2024 Aug 19;14(8):460. doi: 10.3390/metabo14080460.
9
Causal Association of Arterial Stiffness With the Risk of Chronic Kidney Disease.动脉僵硬度与慢性肾脏病风险的因果关联
JACC Asia. 2023 Dec 12;4(6):444-453. doi: 10.1016/j.jacasi.2023.10.010. eCollection 2024 Jun.
10
Ultrafiltration Patterns during Automated Peritoneal Dialysis: Findings and Insights to Peritoneal Physiology.自动化腹膜透析过程中的超滤模式:对腹膜生理的发现与见解
Kidney360. 2024 Nov 1;5(11):1683-1691. doi: 10.34067/KID.0000000000000506. Epub 2024 Jul 8.
重新评估白蛋白作为肾脏疾病的营养标志物。
J Am Soc Nephrol. 2010 Feb;21(2):223-30. doi: 10.1681/ASN.2009020213. Epub 2010 Jan 14.
4
Arterial pulse wave velocity and peritoneal transport characteristics independently predict hospitalization in Chinese peritoneal dialysis patients.动脉脉搏波速度和腹膜转运特性独立预测中国腹膜透析患者的住院情况。
Perit Dial Int. 2010 Jan-Feb;30(1):80-5. doi: 10.3747/pdi.2008.00270.
5
Does TREAT give the boot to ESAs in the treatment of CKD anemia?在慢性肾脏病贫血的治疗中,TREAT是否会淘汰促红细胞生成素类药物?
J Am Soc Nephrol. 2010 Jan;21(1):2-6. doi: 10.1681/ASN.2009111127. Epub 2009 Dec 24.
6
Aortic PWV in chronic kidney disease: a CRIC ancillary study.慢性肾脏病患者的主动脉脉搏波速度:CRIC 辅助研究。
Am J Hypertens. 2010 Mar;23(3):282-9. doi: 10.1038/ajh.2009.240. Epub 2009 Dec 17.
7
Association of inflammation and protein-energy wasting with endothelial dysfunction in peritoneal dialysis patients.炎症和蛋白能量消耗与腹膜透析患者内皮功能障碍的关系。
Nephrol Dial Transplant. 2010 Apr;25(4):1266-71. doi: 10.1093/ndt/gfp598. Epub 2009 Nov 19.
8
Cardiovascular and noncardiovascular mortality among patients starting dialysis.开始透析的患者的心血管和非心血管死亡率。
JAMA. 2009 Oct 28;302(16):1782-9. doi: 10.1001/jama.2009.1488.
9
Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions.使用先进腹膜透析液的腹膜透析患者的死亡率和技术失败率
Am J Kidney Dis. 2009 Oct;54(4):711-20. doi: 10.1053/j.ajkd.2009.05.014. Epub 2009 Jul 19.
10
Long-term mortality and cardiovascular risk stratification of peritoneal dialysis patients using a combination of inflammation and calcification markers.使用炎症和钙化标志物组合对腹膜透析患者进行长期死亡率和心血管风险分层。
Nephrol Dial Transplant. 2009 Dec;24(12):3826-33. doi: 10.1093/ndt/gfp325. Epub 2009 Jul 2.